Barclays’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-16,000
| Closed | -$7.44M | – | 5499 |
|
|
2024
Q3 | $7.44M | Sell |
16,000
-21,600
| -57% | -$10.4M | ﹤0.01% | 1709 |
|
|
2024
Q2 | $17.6M | Buy |
37,600
+34,300
| +1,039% | +$14.9M | 0.01% | 981 |
|
|
2024
Q1 | $1.38M | Buy |
3,300
+2,100
| +175% | +$888K | ﹤0.01% | 2872 |
|
|
2023
Q4 | $488K | Buy |
1,200
+200
| +20% | +$73.9K | ﹤0.01% | 3888 |
|
|
2023
Q3 | $348K | Buy |
+1,000
| New | +$350K | ﹤0.01% | 3004 |
|
|
2023
Q1 | – | Sell |
-39,200
| Closed | -$11.3M | – | 5375 |
|
|
2022
Q4 | $11.3M | Buy |
39,200
+18,000
| +85% | +$5.49M | 0.01% | 1146 |
|
|
2022
Q3 | $6.14M | Hold |
21,200
| – | – | 0.01% | 1053 |
|
|
2022
Q2 | $5.97M | Hold |
21,200
| – | – | ﹤0.01% | 1247 |
|
|
2022
Q1 | $5.53M | Sell |
21,200
-59,200
| -74% | -$14M | ﹤0.01% | 1197 |
|
|
2021
Q4 | $17.7M | Buy |
+80,400
| New | +$15.6M | 0.01% | 994 |
|
|
2021
Q3 | – | Sell |
-110,100
| Closed | -$22.2M | – | 5042 |
|
|
2021
Q2 | $22.2M | Buy |
110,100
+48,500
| +79% | +$10.1M | 0.01% | 848 |
|
|
2021
Q1 | $13.2M | Buy |
61,600
+45,700
| +287% | +$10M | 0.01% | 967 |
|
|
2020
Q4 | $3.76M | Buy |
15,900
+11,600
| +270% | +$2.66M | ﹤0.01% | 1725 |
|
|
2020
Q3 | $1.17M | Hold |
4,300
| – | – | ﹤0.01% | 2550 |
|
|
2020
Q2 | $1.25M | Sell |
4,300
-22,900
| -84% | -$6.21M | ﹤0.01% | 2552 |
|
|
2020
Q1 | $6.47M | Sell |
27,200
-73,200
| -73% | -$16.8M | 0.01% | 1273 |
|
|
2019
Q4 | $22M | Sell |
100,400
-4,500
| -4% | -$911K | 0.01% | 912 |
|
|
2019
Q3 | $17.8M | Sell |
104,900
-2,400
| -2% | -$425K | 0.01% | 947 |
|
|
2019
Q2 | $19.7M | Sell |
107,300
-8,400
| -7% | -$1.47M | 0.01% | 943 |
|
|
2019
Q1 | $21.3M | Buy |
115,700
+103,100
| +818% | +$19M | 0.01% | 816 |
|
|
2018
Q4 | $2.09M | Sell |
12,600
-132,900
| -91% | -$23M | ﹤0.01% | 2371 |
|
|
2018
Q3 | $28M | Buy |
145,500
+22,400
| +18% | +$3.99M | 0.02% | 684 |
|
|
2018
Q2 | $20.9M | Buy |
123,100
+90,600
| +279% | +$14M | 0.02% | 766 |
|
|
2018
Q1 | $5.3M | Sell |
32,500
-265,500
| -89% | -$43.4M | ﹤0.01% | 1590 |
|
|
2017
Q4 | $44.7M | Buy |
298,000
+67,400
| +29% | +$9.98M | 0.04% | 459 |
|
|
2017
Q3 | $35.1M | Buy |
230,600
+30,100
| +15% | +$4.53M | 0.04% | 434 |
|
|
2017
Q2 | $25.8M | Sell |
200,500
-21,600
| -10% | -$2.6M | 0.03% | 489 |
|
|
2017
Q1 | $24.3M | Buy |
222,100
+122,700
| +123% | +$10.8M | 0.03% | 481 |
|
|
2016
Q4 | $7.32M | Buy |
99,400
+11,800
| +13% | +$960K | 0.01% | 1128 |
|
|
2016
Q3 | $7.64M | Buy |
87,600
+41,500
| +90% | +$3.92M | 0.01% | 1025 |
|
|
2016
Q2 | $3.97M | Buy |
46,100
+41,900
| +998% | +$3.62M | 0.01% | 1479 |
|
|
2016
Q1 | $332K | Sell |
4,200
-32,700
| -89% | -$2.96M | ﹤0.01% | 3477 |
|
|
2015
Q4 | $4.61M | Sell |
36,900
-28,200
| -43% | -$3.4M | 0.01% | 1376 |
|
|
2015
Q3 | $6.77M | Buy |
65,100
+44,900
| +222% | +$5.77M | 0.01% | 1174 |
|
|
2015
Q2 | $2.48M | Hold |
20,200
| – | – | ﹤0.01% | 2060 |
|
|
2015
Q1 | $2.36M | Sell |
20,200
-452,900
| -96% | -$54.3M | ﹤0.01% | 2154 |
|
|
2014
Q4 | $55.8M | Buy |
473,100
+46,300
| +11% | +$5.21M | 0.05% | 313 |
|
|
2014
Q3 | $47.8M | Sell |
426,800
-828,100
| -66% | -$78.8M | 0.05% | 342 |
|
|
2014
Q2 | $118M | Buy |
1,254,900
+536,900
| +75% | +$37.6M | 0.12% | 119 |
|
|
2014
Q1 | $50.3M | Buy |
718,000
+294,300
| +69% | +$23.3M | 0.06% | 296 |
|
|
2013
Q4 | $31.4M | Sell |
423,700
-149,300
| -26% | -$10.4M | 0.03% | 528 |
|
|
2013
Q3 | $43M | Sell |
573,000
-51,100
| -8% | -$4.07M | 0.05% | 341 |
|
|
2013
Q2 | $50M | Buy |
+624,100
| New | +$46M | 0.06% | 260 |
|
Other funds holding VRTX
VCM
VPM
Barclays's VRTX Position: Q1 2026 in Review
Barclays reduced its Vertex Pharmaceuticals (VRTX) stake by 22% in Q1 2026, selling an estimated $86M and leaving 663,263 shares worth $296M. The position accounts for 0.07% of the portfolio, ranked #204.
Barclays first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $437M in Q3 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Barclays held 663,263 shares of Vertex Pharmaceuticals worth $296M as of Q1 2026.
- Barclays sold 184,495 Vertex Pharmaceuticals shares in Q1 2026, an estimated $86M.
- Vertex Pharmaceuticals made up 0.07% of Barclays's portfolio in Q1 2026, its #204 holding.
- Barclays first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Barclays's Vertex Pharmaceuticals position peaked at $437M in Q3 2024.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.